Helena T. Hogberg

1.
Eike Cöllen, Kristina Bartmann, Jonathan Blum, et al. Mapping out strategies to further develop human-relevant, new approach methodology (NAM)-based developmental neurotoxicity (DNT) testing. ALTEX - Alternatives to animal experimentation. 2025. doi:10.14573/altex.2501091
View Full Reference
1.
Shu Yang, Kelly E. Carstens, Ibukunoluwa Ipaye, et al. High-throughput cytokine detection platform for evaluation of chemical induced microglial activation. SLAS Technology. 2025;35. doi:10.1016/j.slast.2025.100347
View Full Reference
1.
Susan J. Debad, Jason Aungst, Kelly Carstens, et al. State of the science on assessing developmental neurotoxicity using new approach methods. ALTEX - Alternatives to animal experimentation. 2025;42(1):121-144. doi:10.14573/altex.2410231
View Full Reference
1.
Ruth A. Roberts, Mamta Behl, Helena T. Hogberg, et al. Use of new approach methodologies (NAMs) in epilepsy research and seizure risk assessment. Drug Discovery Today. 2025;31(1):104569. doi:10.1016/j.drudis.2025.104569
View Full Reference
1.
Manuela Cassotta, Hugo Geerts, Lise Harbom, et al. The future of Parkinson’s disease research: A new paradigm of human-specific investigation is necessary… and possible. ALTEX. 2022;39(4):694-709. doi:10.14573/altex.2203161
View Full Reference
1.
David Pamies, Marcel Leist, Sandra Coecke, et al. Guidance document on Good Cell and Tissue Culture Practice 2.0 (GCCP 2.0). Alternatives to Animal Experimentation. 2022;39(1):30-70. doi:10.14573/altex.2111011
View Full Reference
1.
Thomas Hartung, Rob De Vries, Sebastian Hoffmann, et al. Toward Good In Vitro Reporting Standards. Alternatives to Animal Experimentation. 2019;36(1):3-17. doi:10.14573/altex.1812191
View Full Reference